This week we pleased to take part to the Imaging User Meeting 2023 of Molecular Devices. The event took place on 9 and 10 May in Copenhagen. It was an amazing opportunity to share our imaging practices with attendees and the scientific community. We appreciated the program, gathering a variety Read more…
A driver oncogene is a gene that, when activated by mutation or altered in expression, contributes importantly to the development and progression of cancer. In other words, alteration of this kind of genes lead to the transformation of a normal cell into a cancerous cell by activating signaling pathways involved Read more…
Elodie is waiting for you on the first floor at Nutr’event 2019! HCS Pharma stand is n° D6/2, on Clubster NHL pavilion. She will be glad to discuss with you about: our in vitro tests for the objectivation of your claims on human cells (e.g. nutraceutical, dermocosmetic claims) our innovative Read more…
We will be present this week and next week in Rotterdam, to talk about 3D cell culture and the importance of the microenvironnement in the relevance of in vitro models. As you known, to mimic human tissues, several parameters need to be taken into account: the target cells, nutrient intake Read more…
HCS pharma has organized its second scientific advisory board! We were pleased to gather around the table (physically or via a Webex visioconference for those who could not make the trip) David Devos, Roméo Cecchelli, George Haase, Karim Si Tayed… and a new board member: Dominique Collard! Dominique is known Read more…
Abstract Pharmacological evaluation of anticancer drugs using 3D in vitro models provides invaluable information for predicting in vivo activity. Artificial matrices are currently available that scale up and increase the power of such 3D models. The aim of the present study was to propose an efficient and robust imaging and Read more…